Literature DB >> 34106427

Loco-regional therapy and the risk of breast cancer-related lymphedema: a systematic review and meta-analysis.

Yan Lin1, Ying Xu1, Changjun Wang1, Yu Song1, Xin Huang1, Xiaohui Zhang1, Xi Cao1, Qiang Sun2.   

Abstract

BACKGROUND: This meta-analysis was designed to assess the association between two loco-regional therapies, regional nodal irradiation (RNI) and axillary lymph node dissection (ALND), and breast cancer-related lymphoedema (BCRL).
METHODS: We searched PubMed, Science Direct, Embase, and BMJ databases for clinical studies published between January 1, 2010 and January 1, 2020, which assessed risk factors and incidence/prevalence of BCRL. Two investigators independently selected articles to extract relative data and calculate corresponding exact binomial 95% confidence intervals (CIs). In total, 93 articles were reviewed, from which 19 studies were selected. The extracted data were pooled using a random-effects mixed model.
RESULTS: The incidence of lymphedema in the selected studies ranged from 3% to 36.7%, with a pooled incidence of 14.29% (95% CI 13.79-14.79). The summary odds ratio/risk ratio (OR/RR) of ALND vs. no-ALND was 3.67 (95% CI 2.25-5.98) with a heterogeneity (I2) of 81% (P < 0.00001). After excluding the studies with an abnormally high risk of lymphedema from self-reporting, the summary hazard ratio (HR) was 2.99 (95% CI 2.44-3.66) with no heterogeneity (I2 = 0%, P = 0.83). The summary OR/RR of patients with vs. without radiotherapy (RT) was 1.82 (95% CI 0.92-3.59), but the RR of RT to breast/chest vs. both axillary and supraclavicular areas was 2.66 (95% CI 0.73-9.70).
CONCLUSION: Regional nodal irradiation has a significantly higher risk for developing lymphedema than irradiation of the breast/chest wall. Axillary dissection and axillary RT have a similar risk for early-onset of breast cancer-related lymphoedema, although the risk trends higher for axillary dissection.
© 2021. The Japanese Breast Cancer Society.

Entities:  

Keywords:  Axillary lymph node dissection (ALND); Breast cancer-related lymphoedema (BCRL); Loco-regional therapy; Regional nodal irradiation (RNI); Risk factor; Sentinel lymph node biopsy (SLND)

Mesh:

Year:  2021        PMID: 34106427     DOI: 10.1007/s12282-021-01263-8

Source DB:  PubMed          Journal:  Breast Cancer        ISSN: 1340-6868            Impact factor:   4.239


  1 in total

1.  Difficulties with defining lymphoedema after axillary dissection for breast cancer.

Authors:  Muhammad Asim; Alvin Cham; Sharmana Banerjee; Rachael Nancekivell; Gaelle Dutu; Catherine McBride; Shelley Cavanagh; Ross Lawrenson; Ian Campbell
Journal:  N Z Med J       Date:  2012-03-09
  1 in total
  2 in total

Review 1.  Experiences of breast cancer survivors with lymphedema self-management: a systematic review of qualitative studies.

Authors:  Xin Fu; Qian Lu; Dong Pang; Aomei Shen; Yi-An Shih; Xiaoxia Wei
Journal:  J Cancer Surviv       Date:  2022-06-30       Impact factor: 4.442

2.  Sentinel Lymph Node Biopsy Alone is Adequate for Chemotherapy Decisions in Postmenopausal Early-Stage Hormone-Receptor-Positive, HER2-Negative Breast Cancer with One to Three Positive Sentinel Lymph Nodes.

Authors:  Olga Kantor; Anna Weiss; Harold J Burstein; Elizabeth A Mittendorf; Tari A King
Journal:  Ann Surg Oncol       Date:  2022-06-28       Impact factor: 4.339

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.